1
|
Al-Zoubi N, Partheniadis I, Aljaberi A, Nikolakakis I. Co-spray Drying Drugs with Aqueous Polymer Dispersions (APDs)-a Systematic Review. AAPS PharmSciTech 2022; 23:140. [PMID: 35538248 DOI: 10.1208/s12249-022-02293-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/25/2022] [Indexed: 11/30/2022] Open
Abstract
Aqueous colloidal dispersions of water-insoluble polymers (APDs) avoid hassles associated with the use of organic solvents and offer processing advantages related to their low viscosity and short processing times. Therefore, they became the main vehicle for pharmaceutical coating of tablets and multiparticulates, a process commonly employed using pan and fluidized-bed machinery. Another interesting although less common processing approach is co-spray drying APDs with drugs in aqueous systems. It enables the manufacture of capsule- and matrix-type microspheres with controllable size and improved processing characteristics in a single step. These microspheres can be further formulated into different dosage forms. This systematic review is based on published research articles and aims to highlight the applicability and opportunities of co-spray drying drugs with APDs in drug delivery.
Collapse
|
2
|
Jain SK, Jain AK, Rajpoot K. Expedition of Eudragit® Polymers in the Development of Novel Drug Delivery Systems. Curr Drug Deliv 2020; 17:448-469. [PMID: 32394836 DOI: 10.2174/1567201817666200512093639] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 01/10/2020] [Accepted: 04/20/2020] [Indexed: 12/16/2022]
Abstract
Eudragit® polymer has been widely used in film-coating for enhancing the quality of products over other materials (e.g., shellac or sugar). Eudragit® polymers are obtained synthetically from the esters of acrylic and methacrylic acid. For the last few years, they have shown immense potential in the formulations of conventional, pH-triggered, and novel drug delivery systems for incorporating a vast range of therapeutics including proteins, vitamins, hormones, vaccines, and genes. Different grades of Eudragit® have been used for designing and delivery of therapeutics at a specific site via the oral route, for instance, in stomach-specific delivery, intestinal delivery, colon-specific delivery, mucosal delivery. Further, these polymers have also shown their great aptitude in topical and ophthalmic delivery. Moreover, available literature evidences the promises of distinct Eudragit® polymers for efficient targeting of incorporated drugs to the site of interest. This review summarizes some potential researches that are being conducted by eminent scientists utilizing the distinct grades of Eudragit® polymers for efficient delivery of therapeutics at various sites of interest.
Collapse
Affiliation(s)
- Sunil Kumar Jain
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| | - Akhlesh K Jain
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| | - Kuldeep Rajpoot
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| |
Collapse
|
3
|
Oliva R, Fraleigh NL, Lewicky JD, Fariñas M, Hernández T, Martel AL, Navarro I, Dagmar GR, Acevedo R, Le HT. Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats. Pharmaceutics 2019; 11:pharmaceutics11120626. [PMID: 31771151 PMCID: PMC6955701 DOI: 10.3390/pharmaceutics11120626] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 11/15/2019] [Accepted: 11/20/2019] [Indexed: 01/04/2023] Open
Abstract
Tobacco smoking is the cause of 20% of Canadian deaths per year. Nicotine vaccines present a promising alternative to traditional smoking cessation products, but to date, no vaccine has been able to move through all phases of clinical trials. We have previously demonstrated that the AFPL1-conjugate nicotine vaccine does not induce systemic or immunotoxicity in a mouse model and that a heterologous vaccination approach is more advantageous than the homologous routes to inducing mucosal and systemic anti-nicotine antibodies. The purpose of this study was to confirm the safety profile of the vaccine in a repeat-dose toxicity study. The heterologous vaccination strategy was again used, and Sprague Dawley rats were administered a dose five times greater than in our previous studies. Physiological conditions, food and water consumption, body temperature, injection site inflammation, relative weights of organs, histopathology, and blood chemistry and hematology were evaluated during the course of the vaccination period to determine the safety of the vaccine. The AFPL1-conjugate nicotine vaccine did not induce clinically relevant changes or induce symptoms that would be associated with toxicity, making it a promising candidate for future investigations.
Collapse
Affiliation(s)
- Reynaldo Oliva
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - Nya L. Fraleigh
- Health Sciences North Research Institute (HSNRI), Sudbury, ON P3E 2H3, Canada; (N.L.F.); (J.D.L.); (A.L.M.)
| | - Jordan D. Lewicky
- Health Sciences North Research Institute (HSNRI), Sudbury, ON P3E 2H3, Canada; (N.L.F.); (J.D.L.); (A.L.M.)
| | - Mildrey Fariñas
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - Tamara Hernández
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - Alexandrine L. Martel
- Health Sciences North Research Institute (HSNRI), Sudbury, ON P3E 2H3, Canada; (N.L.F.); (J.D.L.); (A.L.M.)
| | - Ingrid Navarro
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - García-Rivera Dagmar
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - Reinaldo Acevedo
- Finlay Institute of Vaccine, Havana 11600, Cuba; (R.O.); (M.F.); (T.H.); (I.N.); (G.-R.D.); (R.A.)
| | - Hoang-Thanh Le
- Health Sciences North Research Institute (HSNRI), Sudbury, ON P3E 2H3, Canada; (N.L.F.); (J.D.L.); (A.L.M.)
- Northern Ontario School of Medicine (NOSM), Laurentian University, Sudbury, ON P3E 2C6, Canada
- Chemistry & Biochemistry and Biology Departments, Laurentian University, Sudbury, ON P3E 2C6, Canada
- Correspondence: ; Tel.: +1-705-523-7300 (ext. 2613)
| |
Collapse
|
4
|
Davitt CJH, Longet S, Albutti A, Aversa V, Nordqvist S, Hackett B, McEntee CP, Rosa M, Coulter IS, Lebens M, Tobias J, Holmgren J, Lavelle EC. Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines. Mucosal Immunol 2019; 12:1055-1064. [PMID: 30953000 PMCID: PMC7746523 DOI: 10.1038/s41385-019-0159-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 01/26/2019] [Accepted: 02/19/2019] [Indexed: 02/07/2023]
Abstract
Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3-4 million cases globally with 100,000-150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, single-component whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses.
Collapse
Affiliation(s)
- Christopher J. H. Davitt
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Stephanie Longet
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Aqel Albutti
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland ,0000 0000 9421 8094grid.412602.3College of Applied Medical Sciences, Qassim University, Buraydah, 52571 Saudi Arabia
| | - Vincenzo Aversa
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Stefan Nordqvist
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Becky Hackett
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Craig P. McEntee
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Monica Rosa
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Ivan S. Coulter
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Michael Lebens
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Joshua Tobias
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Jan Holmgren
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Ed C. Lavelle
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland ,0000 0004 1936 9705grid.8217.cCentre for Research on Adaptive Nanostructures and Nanodevices (CRANN) & Advanced Materials Bio-Engineering Research Centre (AMBER), Trinity College Dublin, Dublin 2, D02 PN40 Ireland
| |
Collapse
|
5
|
Davitt CJH, McNeela EA, Longet S, Tobias J, Aversa V, McEntee CP, Rosa M, Coulter IS, Holmgren J, Lavelle EC. A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens. J Control Release 2016; 233:162-73. [PMID: 27157995 DOI: 10.1016/j.jconrel.2016.05.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2016] [Revised: 04/29/2016] [Accepted: 05/01/2016] [Indexed: 12/21/2022]
Abstract
Diarrhoeal infections are a major cause of morbidity and mortality with enterotoxigenic Escherichia coli (ETEC) and cholera imposing a significant global burden. There is currently no licensed vaccine for ETEC. Development of new nonliving oral vaccines has proven difficult due to the physicochemical and immunological challenges associated with the oral route. This demands innovative delivery solutions to protect antigens, control their release and build in immune-stimulatory activity. We describe the Single Multiple Pill® (SmPill®) vaccine formulation which combines the benefits of enteric polymer coating to protect against low gastric pH, a dispersed phase to control release and aid the solubility of non-polar components and an optimized combination of adjuvant and antigen to promote mucosal immunity. We demonstrate the effectiveness of this system with whole cell killed E. coli overexpressing colonization factor antigen I (CFA/I), JT-49. Alpha-galactosylceramide was identified as a potent adjuvant within SmPill® that enhanced the immunogenicity of JT-49. The bacteria associated with the dispersed phase were retained within the capsules at gastric pH but released at intestinal pH. Vaccination with an optimized SmPill® formulation promoted CFA/I-specific immunoglobulin A (IgA) responses in the intestinal mucosa in addition to serum IgG and a solubilized adjuvant was indispensable for efficacy.
Collapse
Affiliation(s)
- Christopher J H Davitt
- Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland
| | - Edel A McNeela
- Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland
| | - Stephanie Longet
- Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland
| | - Joshua Tobias
- University of Gothenburg Vaccine Research Institute (GUVAX), Dept. of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Vincenzo Aversa
- Sigmoid Pharma Limited, Dublin City University, The Invent Centre, DCU, Glasnevin, Dublin 9, Ireland
| | - Craig P McEntee
- Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland
| | - Monica Rosa
- Sigmoid Pharma Limited, Dublin City University, The Invent Centre, DCU, Glasnevin, Dublin 9, Ireland
| | - Ivan S Coulter
- Sigmoid Pharma Limited, Dublin City University, The Invent Centre, DCU, Glasnevin, Dublin 9, Ireland
| | - Jan Holmgren
- University of Gothenburg Vaccine Research Institute (GUVAX), Dept. of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Ed C Lavelle
- Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland; Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN); Advanced Materials Bio-Engineering Research Centre (AMBER), Trinity College Dublin, Dublin 2, D02 PN40, Ireland.
| |
Collapse
|
6
|
Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 2015; 91:52-69. [PMID: 25817337 DOI: 10.1016/j.addr.2015.03.007] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Revised: 02/25/2015] [Accepted: 03/12/2015] [Indexed: 01/22/2023]
Abstract
While the majority of human pathogens infect the body through mucosal sites, most licensed vaccines are injectable. In fact the only mucosal vaccine that has been widely used globally for infant and childhood vaccination programs is the oral polio vaccine (OPV) developed by Albert Sabin in the 1950s. While oral vaccines against Cholera, rotavirus and Salmonella typhi have also been licensed, the development of additional non-living oral vaccines against these and other enteric pathogens has been slow and challenging. Mucosal vaccines can elicit protective immunity at the gut mucosa, in part via antigen-specific secretory immunoglobulin A (SIgA). However, despite their advantages over the injectable route, oral vaccines face many hurdles. A key challenge lies in design of delivery strategies that can protect antigens from degradation in the stomach and intestine, incorporate appropriate immune-stimulatory adjuvants and control release at the appropriate gastrointestinal site. A number of systems including micro and nanoparticles, lipid-based strategies and enteric capsules have significant potential either alone or in advanced combined formulations to enhance intestinal immune responses. In this review we will outline the opportunities, challenges and potential delivery solutions to facilitate the development of improved oral vaccines for infectious enteric diseases.
Collapse
|